Veronica Hackethal, MD, reports for Medscape on a recent study published in “Blood”. Brentuximab vedotin, currently approved for other uses, has just exited a phase 2 study for use as a first-line option against Hodgkin’s lymphoma. The results look good, and that’s important for a lot of elderly with the cancer. The reason is, the regimen is very well tolerated amongst the elderly, much more so than standard chemotherapy. Because the drug is already on the market, it may be available for immediate use; so if you or an elderly loved one suffer from the disease, ask your doctor about it.